Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, DHHS, Bethesda, MD 20892, USA.
J Mol Biol. 2012 Sep 14;422(2):230-44. doi: 10.1016/j.jmb.2012.05.024. Epub 2012 May 30.
Dimerization is indispensible for release of the human immunodeficiency virus protease (PR) from its precursor (Gag-Pol) and ensuing mature-like catalytic activity that is crucial for virus maturation. We show that a single-chain Fv fragment (scFv) of a previously reported monoclonal antibody (mAb1696), which recognizes the N-terminus of PR, dissociates a dimeric mature D25N PR mutant with an enhanced dimer dissociation constant (K(d)) in the sub-micromolar range to form predominantly a monomer-scFv complex at a 1:1 ratio, along with small (5-10%) amounts of a dimer-scFv complex. Enzyme kinetics indicate a mixed mechanism of inhibition of the wild-type PR, which exhibits a K(d)<10nM, with effects both on K(m) and k(cat) at an scFv-to-PR ratio of 10:1. ScFv binds to the N-terminal peptide P(1)QITLW(6) of PR and to PR monomers with dissociation constants of ≤30 nM and ~100 nM, respectively. Consistent with an ~400-fold increase in the dissociation of the antibody (K(Ab)) on even addition of an acetyl group to P(1) of the peptide, the antibody fails to inhibit N-terminal autoprocessing of the PR from a model precursor (at ~5 μM). However, subsequent to this cleavage, it sequesters the PR, thus blocking autoprocessing at its C-terminus. A second monoclonal antibody [PRM1 (human monoclonal antibody to PR)], which recognizes part of the flap region (residues 41-47) of the mature PR and its precursor, does not inhibit autoprocessing and ensuing catalytic activity. However, its failure to recognize drug-resistant clinical mutants of PR may be beneficial to monitor the selection of mutations in this region under drug pressure.
二聚化对于人类免疫缺陷病毒蛋白酶(PR)从其前体(Gag-Pol)中的释放以及随后产生成熟样的催化活性至关重要,这种活性对于病毒成熟至关重要。我们表明,先前报道的单克隆抗体(mAb1696)的单链 Fv 片段(scFv)识别 PR 的 N 端,可分离二聚成熟 D25N PR 突变体,其亚微摩尔范围内的二聚体解离常数(K(d))增强至形成主要为单体-scFv 复合物的 1:1 比,同时还有少量(5-10%)的二聚体-scFv 复合物。酶动力学表明,野生型 PR 的抑制作用具有混合机制,其 K(d)<10nM,在 scFv 与 PR 的比例为 10:1 时,对 K(m)和 k(cat)均有影响。scFv 结合到 PR 的 N 端肽 P(1)QITLW(6)和 PR 单体,解离常数分别为≤30 nM 和~100 nM。与 P(1)肽上甚至添加一个乙酰基可使抗体(K(Ab))的解离增加约 400 倍一致,该抗体未能抑制模型前体中 PR 的 N 端自切割(约 5 μM)。然而,在此切割之后,它隔离了 PR,从而阻止了其 C 端的自切割。第二种单克隆抗体[PRM1(针对 PR 的人单克隆抗体)]识别成熟 PR 及其前体的 flap 区域(残基 41-47)的一部分,不抑制自切割和随后的催化活性。然而,它不能识别 PR 的耐药临床突变体,这可能有利于在药物压力下监测该区域突变的选择。